tiprankstipranks
Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
PremiumRatingsKura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
28d ago
Bullish Outlook for Kura Oncology: Buy Rating Affirmed Amid Optimism for Ziftomenib Approval and Competitive Advantage
Premium
Ratings
Bullish Outlook for Kura Oncology: Buy Rating Affirmed Amid Optimism for Ziftomenib Approval and Competitive Advantage
28d ago
Kura Oncology’s Promising Pipeline and Strategic Focus Justify Buy Rating
Premium
Ratings
Kura Oncology’s Promising Pipeline and Strategic Focus Justify Buy Rating
29d ago
Is KURA a Buy, Before Earnings?
PremiumPre-EarningsIs KURA a Buy, Before Earnings?
1M ago
Kura Oncology reports inducement grants under Nasdaq listing rule
Premium
The Fly
Kura Oncology reports inducement grants under Nasdaq listing rule
2M ago
Kura Oncology price target raised to $36 from $34 at Wedbush
Premium
The Fly
Kura Oncology price target raised to $36 from $34 at Wedbush
2M ago
Kura Oncology price target raised to $40 from $37 at H.C. Wainwright
PremiumThe FlyKura Oncology price target raised to $40 from $37 at H.C. Wainwright
2M ago
Kura Oncology’s Strategic Path to Approval: Buy Rating Based on Promising Trial Outcomes and FDA Alignment
Premium
Ratings
Kura Oncology’s Strategic Path to Approval: Buy Rating Based on Promising Trial Outcomes and FDA Alignment
2M ago
Kura Oncology’s Promising Progress and Strategic Alignment Drive Buy Rating
Premium
Ratings
Kura Oncology’s Promising Progress and Strategic Alignment Drive Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100